Orthocell Ltd (AU:OCC)
ASX:OCC
Top Page
Orthocell Ltd
(Sydney:OCC)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.78
▼(-3.33% Downside)
Action:ReiteratedDate:11/19/25
Orthocell Ltd faces significant challenges with profitability and cash flow, as reflected in its financial performance score. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to negative earnings. These factors collectively result in a low overall stock score.
Positive Factors
Revenue Growth
Sustained top-line growth indicates increasing adoption of Orthocell’s products and supports scale economies in manufacturing and distribution. Over 2–6 months, growing revenue provides a firmer base to improve margins and justify further investment in commercialization and R&D.
Negative Factors
Negative Profitability
Ongoing negative net margins and returns (negative ROE) mean the business cannot yet self-sustain profitability. Persisting losses will constrain reinvestment, increase reliance on external capital, and slow path to durable operating leverage over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line growth indicates increasing adoption of Orthocell’s products and supports scale economies in manufacturing and distribution. Over 2–6 months, growing revenue provides a firmer base to improve margins and justify further investment in commercialization and R&D.
Read all positive factors
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$222.47M
Dividend YieldN/A
Average Volume (3M)820.75K
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth42.05%
EPS Growth-0.84%
CountryAU
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding271,307,950
10 Day Avg. Volume747,972
30 Day Avg. Volume820,745
Financial Highlights & Ratios
PEG Ratio-3.76
Price to Book (P/B)18.08
Price to Sales (P/S)34.89
P/FCF Ratio-29.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.15Price Target Upside41.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$13.00M
Orthocell Ltd Business Overview & Revenue Model
Company Description
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived coll...
How the Company Makes Money
Orthocell makes money primarily by selling its commercial regenerative medicine products and associated services into healthcare markets. Key revenue streams include: (1) Product sales of its collagen-based implant/device products used in surgical...
Orthocell Ltd Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.41M | 7.55M | 5.32M | 4.24M | 1.53M | 1.02M |
| Gross Profit | 3.50M | 4.80M | 3.69M | 3.06M | 832.52K | 299.88K |
| EBITDA | -15.31M | -13.43M | -11.68M | -10.34M | -11.52M | -11.67M |
| Net Income | -12.48M | -8.57M | -7.18M | -6.25M | -9.11M | -9.04M |
Balance Sheet | ||||||
| Total Assets | 59.80M | 35.24M | 26.62M | 29.61M | 37.90M | 19.33M |
| Cash, Cash Equivalents and Short-Term Investments | 44.37M | 28.62M | 20.61M | 24.82M | 11.02M | 16.33M |
| Total Debt | 835.79K | 576.89K | 689.69K | 562.30K | 507.56K | 621.72K |
| Total Liabilities | 18.64M | 20.67M | 22.08M | 23.46M | 27.99M | 2.46M |
| Stockholders Equity | 41.16M | 14.57M | 4.53M | 6.15M | 9.90M | 16.87M |
Cash Flow | ||||||
| Free Cash Flow | -12.21M | -9.04M | -7.45M | 13.96M | -6.80M | -4.82M |
| Operating Cash Flow | -12.05M | -8.68M | -6.51M | 14.59M | -6.26M | -4.63M |
| Investing Cash Flow | -42.26M | -359.06K | -942.02K | -631.56K | -535.02K | -188.52K |
| Financing Cash Flow | 30.84M | 17.05M | 3.24M | -164.61K | 1.49M | 709.15K |
Orthocell Ltd Technical Analysis
Neutral
0.81
Price Trends
0.86
Negative
0.95
Negative
1.10
Negative
Market Momentum
-0.01
Negative
51.10
Neutral
84.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OCC, the sentiment is Neutral. The current price of 0.81 is above the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.86, and below the 200-day MA of 1.10, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.10 is Neutral, neither overbought nor oversold. The STOCH value of 84.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:OCC.
Orthocell Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$70.05M | -7.57 | -179.37% | ― | ― | 16.61% | |
52 Neutral | AU$2.74B | ― | -14.02% | ― | 198.58% | 3.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$9.67M | -2.68 | -29.91% | ― | 178.06% | -2.49% | |
42 Neutral | AU$28.32M | -6.84 | -49.25% | ― | ― | ― | |
42 Neutral | AU$9.43M | -1.00 | -218.76% | ― | ― | ― | |
41 Neutral | AU$222.47M | -12.98 | -44.80% | ― | 42.05% | -0.84% |
* Healthcare Sector Average
AU:OCC
Orthocell Ltd
0.82
-0.66
-44.59%
AU:CYP
Cynata Therapeutics Limited
0.30
0.11
59.46%
AU:1AI
Living Cell Technologies
0.01
<0.01
40.00%
AU:MSB
Mesoblast Limited
2.12
0.46
27.71%
AU:TRP
Tissue Repair Ltd
0.16
-0.08
-33.33%
AU:CMB
Regeneus Ltd.
0.35
0.06
23.21%
Orthocell Ltd Corporate Events
Orthocell to Outline March-Quarter Results and Remplir Rollout in Investor Webinar
Apr 14, 2026
Orthocell Ltd will release its quarterly results for the period ended 31 March 2026 on 20 April and host an investor webinar the same day, led by its chair, chief executive and chief financial officer. The briefing will cover financial performance...
Orthocell courts investors with biotech presentation as global product rollout advances
Mar 31, 2026
Orthocell Ltd, a Perth-based regenerative medicine specialist, is expanding a suite of products aimed at repairing bone, nerve, tendon and cartilage injuries, anchored by collagen medical devices and autologous cell therapies. Its lead products, i...
Orthocell reports lapse of 16,567 retention rights, trimming potential equity
Mar 16, 2026
Orthocell Ltd has notified the market that 16,567 retention rights, classified as OCCAAH securities, have lapsed after conditions attached to these rights were not met or became incapable of being satisfied. The cessation of these conditional secu...
Orthocell Issues New Retention and Performance Rights Under Employee Incentive Plan
Mar 16, 2026
Orthocell Ltd has issued 654,963 retention rights and 240,065 performance rights as unquoted securities under its employee incentive scheme, effective 16 March 2026. The new rights, which are subject to transfer restrictions and will not be quoted...
Orthocell Taps LEDA for UK Launch of Remplir Nerve Repair Device
Mar 9, 2026
Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir nerve repair device in the United Kingdom, a move that underpins its strategy to penetrate the UK and EU peripheral nerve repair market estimated at US$750 mill...
Orthocell director Michael McNulty increases on‑market shareholding
Feb 25, 2026
Orthocell Limited has reported a change in the holdings of director Michael McNulty, who maintains both direct and indirect interests in the company’s securities through personal holdings, a family trust structure and his spouse. The disclos...
Orthocell Director Increases Shareholding Through On-Market Purchase
Feb 25, 2026
Orthocell has disclosed a change in director John Van Der Wielen’s interests following an on‑market purchase of 32,500 ordinary shares for $31,337. The transaction increases his direct equity exposure while leaving his 4,000,000 unlist...
Orthocell posts record half-year revenue as global expansion gains pace
Feb 23, 2026
Orthocell has reported record first-half FY26 revenue of $6.2 million, up 48% year-on-year, driven by rising adoption of its Striate+ and Remplir products and improved gross margins of 55%. The company remains loss-making, with a $5.2 million net ...
Orthocell Issues Confidential US Market Update with Standard Legal Disclaimers
Feb 1, 2026
Orthocell Ltd has issued a US market and operational update presentation, but the released text consists solely of standard legal and confidentiality disclaimers typically accompanying investor or corporate communications. The document outlines th...
Orthocell to Brief Investors on US Rollout of Remplir and Operational Progress
Jan 29, 2026
Orthocell Limited will host an investor webinar on 2 February 2026 to provide an operational update, with a particular focus on the rollout of its Remplir nerve repair device in the United States. The briefing, led by the company’s chairman ...
Orthocell Posts Record Revenue as Remplir Global Rollout Accelerates
Jan 18, 2026
Orthocell reported its seventh consecutive quarter of record revenue, posting $3.2 million for the December 2025 quarter, up 45% year on year, driven by accelerating adoption of its Remplir nerve repair device and initial US sales. Backed by $49.4...
Orthocell Deepens Stake in Marine Biomedical and Secures Rights to PearlBone Bone Regeneration Technology
Jan 15, 2026
Orthocell has executed a binding agreement with Marine Biomedical Pty Ltd, lifting its equity stake from 1.72% to 11.7% for AU$1.05 million and securing a first right of refusal over global distribution rights for PearlBone, a next-generation bone...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.